Immune hemolytic anemia caused by drugs

Bibliography

• Petz LD, Garratty G. Immune Hemolytic Anemias. 2nd edition. Churchill Livingstone; Philadelphia: 2004
   Google Scholar
• Aster RH. Can drugs cause autoimmune thrombocytopenic purpura? Semin Hematol 2000;37:229-38
   PubMed Web of Science ®Google Scholar
• Petz LD, Garratty G. Acquired Immune Hemolytic Anemias. Churchill Livingstone; New York: 1980
   Google Scholar
• Garratty G, Arndt PA. An update on drug-induced immune hemolytic anemia. Immunohematology 2007;23:105-19
   PubMedGoogle Scholar
• Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol 2005;42:137-44
   PubMed Web of Science ®Google Scholar
• Johnson ST, Fueger JT, Gottschall JL. One center's experience: the serology and drugs associated with drug-induced immune hemolytic anemia – a new paradigm. Transfusion 2007;47:697-702
   PubMed Web of Science ®Google Scholar
• Landsteiner K. The Specificity of Serological Reactions (revised ed). Harvard University Press; Cambridge, MA: 1947. p. 85
   Google Scholar
• Eisen HN, Carsten ME, Belman S. Studies of hypersensitivity to low molecular weight substances. III. The 2,4 dinitrophenyl group as a determinant in the precipitin reaction. J Immunol 1954;73:296-308
   PubMed Web of Science ®Google Scholar
• De Weck AL. Low molecular weight antigens. In: Sela M, editor. The Antigens. Volume 2 Academic Press; New York: 1974. p. 141-248
   Google Scholar
• Garratty G, Petz LD. Drug-induced immune hemolytic anemia. Am J Med 1975;58:398-407
   PubMed Web of Science ®Google Scholar
• Habibi B. Drug- induced red blood cell autoantibodies co-developed with drug specific antibodies causing haemolytic anaemias. Br J Haematol 1985;61:139-43
   PubMed Web of Science ®Google Scholar
• Mueller-Eckhardt C, Salama A. Drug-induced immune cytopenias: a unifying pathogenetic concept with special emphasis on the role of drug metabolites. Transfus Med Rev 1990;4:69-77
   PubMedGoogle Scholar
• Shulman NR, Reid DM. Mechanisms of drug-induced immunologically mediated cytopenias. Transfus Med Rev 1993;VII:215-29
   Google Scholar
• Gralnick HR, Wright LD, McGinniss MH. Coombs' positive reactions associated with sodium cephalothin therapy. JAMA 1967;199:135-6
   Web of Science ®Google Scholar
• Molthan L, Reidenberg MM, Eichman MF. Positive direct Coombs tests due to cephalothin. NEJM 1967;277:123-5
   PubMed Web of Science ®Google Scholar
• Spath P, Garratty G, Petz LD. Studies on the immune response to penicillin and cephalothin in humans. II. Immunohematologic reactions to cephalothin administration. J Immunol 1971;107:860-9
   PubMed Web of Science ®Google Scholar
• Garratty G, Arndt PA. Positive direct antiglobulin tests and haemolytic anaemia following therapy with beta-lactamase inhibitor containing drugs may be associated with nonimmunologic adsorption of protein onto red blood cells. Br J Haematol 1998;100:777-83
   PubMed Web of Science ®Google Scholar
• Broadberry RE, Farren TW, Bevin SV, Tazobactam-induced haemolytic anaemia, possibly caused by non-immunological adsorption of IgG onto patient's red cells. Transfus Med 2004;14:53-7
   PubMed Web of Science ®Google Scholar
• Arndt P, Garratty G, Isaak E, Positive direct antiglobulin tests associated with oxaliplatin can be due to drug antibody and/or drug-induced nonimmunologic protein adsorption. Transfusion 2009;49:711-18
   PubMed Web of Science ®Google Scholar
• Arndt PA, Garratty G. Can nonspecific protein coating of RBCs lead to increased RBC destruction? Drug-treated RBCs with positive antiglobulin tests due to nonspecific protein uptake give positive monocyte monolayer assays [abstract]. Transfusion 2000;40:29S
   Web of Science ®Google Scholar
• Bressler RB, Huston DP. Piperacillin-induced anemia and leucopenia. South Med J 1986;79:255-6
   PubMed Web of Science ®Google Scholar
• Johnson ST, Auer DE, Fueger JT, Aster RH. Piperacillin-dependent antibody with relative specificity reacting with drug treated red cells and untreated red cells in the presence of drug [abstract]. Transfusion 1994;34:70S
   Web of Science ®Google Scholar
• Thickett KM, Wildman MJ, Fegan CD, Stableforth DE. Hemolytic anemia following treatment with piperacillin in a patient with cystic fibrosis. J Antimicrob Chemother 1999;43:435-6
   PubMed Web of Science ®Google Scholar
• Arndt PA, Garratty G, Hill J, Two cases of immune haemolytic anaemia, associated with anti-piperacillin, detected by the “immune complex” method. Vox Sang 2002;83:273-8
   PubMed Web of Science ®Google Scholar
• Johnson ST. Warm autoantibody or drug-dependent antibody? That is the question!. Immunohematology 2007;23:161-4
   PubMedGoogle Scholar
• Leger RM, Arndt PA, Garratty G. Serological studies of piperacillin antibodies. Transfusion 2008;48:2429-34
   PubMed Web of Science ®Google Scholar
• Garcia Gala JM, Vasquez AS, Rodriquez Vicente P, Morante Pombo C. Immune hemolysis due to piperacillin/tazobactam. Transfus Apher Sci 2009;40:97-8
   PubMed Web of Science ®Google Scholar
• Bandara M, Seder DB, Garratty G, Piperacillin-induced immune hemolytic anemia in an adult with cystic fibrosis. Case Rep Med 2010; [Epub ahead of print]
   PubMedGoogle Scholar
• Mayer B, Yurik S, Salama A. Piperacillin-induced immune hemolysis: new cases and a concise review of the literature. Transfusion 2010;50:1135-8
   PubMed Web of Science ®Google Scholar
• Arndt PA, Leger RM, Garratty G. Serological characteristics of anti-piperacillin in seventeen patients with drug-induced immune hemolytic anemia [abstract]. Transfusion 2010;50:37A
   Web of Science ®Google Scholar
• Lohiya G-S, Tan-Figueroa L, Krishna V. Piperacillin-induced immune hemolysis presenting with tachycardia and cardiac arrest. Case Rep Med 2011;2011:816497
   PubMedGoogle Scholar
• Gehrie E, Neff AT, Ciombor NK, Profound piperacillin-mediated drug-induced immune hemolysis in a patient with cystic fibrosis. Transfusion 2012;52:4-5
   PubMed Web of Science ®Google Scholar
• Garratty G. Immune cytopenia associated with antibiotics. Trans Med Rev 1993;VII:255-67
   Google Scholar
• Garratty G. Drug-induced immune hemolytic anemia. Hematol Am Soc Hematol Educ Program 2009;24:73-9
   Google Scholar
• Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev 2010;24:143-50
   PubMed Web of Science ®Google Scholar
• DeTorres OH. Hemolytic anemia and pancytopenia induced by cefoxitin. Drug Intell Clin Pharm 1983;17:816-18
   PubMedGoogle Scholar
• Branch DR, Berkowitz LR, Becker RL, Extravascular hemolysis following the administration of cefamandole. Am J Hematol 1985;18:213-19
   PubMed Web of Science ®Google Scholar
• Arndt PA, Leger RM, Garratty G. Serology of antibodies to second- and third-generation cephalosporins associated with immune hemolytic anemia and/or positive direct antiglobulin tests. Transfusion 1999;39:1239-46
   PubMed Web of Science ®Google Scholar
• Garratty G, Nance S, Lloyd M, Domen R. Fatal immune hemolytic anemia due to cefotetan. Transfusion 1992;32:269-71
   PubMed Web of Science ®Google Scholar
• Gallagher NI, Schergen AK, Sokol-Anderson ML, Severe immune-mediated hemolytic anemia secondary to treatment with cefotetan. Transfusion 1992;32:266-8
   PubMed Web of Science ®Google Scholar
• Wagner BK, Heaton AH, Flink JR. Cefotetan disodium-induced hemolytic anemia. Ann Pharmacother 1992;26:199-200
   PubMed Web of Science ®Google Scholar
• Garratty G, Leger RM, Arndt PA. Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures. Am J Obstet Gynecol 1999;181:103-4
   PubMed Web of Science ®Google Scholar
• Arndt P, Garratty G. Is severe immune hemolytic anemia, following a single dose of cefotetan, associated with the presence of “naturally-occurring” anti-cefotetan? [abstract]. Transfusion 2001;41:24S
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. New animal drugs; cephalosporin drugs; extralabel animal drug use; order of prohibition. Fed Regis 2012;77:735-44
   Google Scholar
• Physicians' Desk Reference: PDR. 66th edition. PDR Network; Montvale, NJ: 2012. p. 735-45
   Google Scholar
• Garratty G, Postoway N, Schwellenbach J, A fatal cases of ceftriaxone (Rocephin)-induced hemolytic anemia associated with intravascular hemolysis. Transfusion 1991;31:176-9
   PubMed Web of Science ®Google Scholar
• Salama A, Gottsche B, Schleiffer T, Mueller-Eckhardt C. ‘Immune complex' mediated intravascular hemolysis due to IgM cephalosporin-dependent antibody. Transfusion 1987;27:460-3
   PubMed Web of Science ®Google Scholar
• Arndt PA, Leger RM, Garratty G. Serologic characteristics of ceftriaxone antibodies in 25 patients with drug-induced immune hemolytic anemia. Transfusion 2012; 52:602-12
   PubMed Web of Science ®Google Scholar
• Shirey RS, Yamada C, Ness PM, King KE. Drug induced immune hemolytic anemia imitating a severe delayed hemolytic transfusion reaction [abstract]. Transfusion 2007;47:185A
   PubMed Web of Science ®Google Scholar
• Shirey R, Iding J, King KE, Drug-induced immune hemolysis mimicking an acute hemolytic transfusion reaction [abstract]. Transfusion 2005;45:100A-1A
   Web of Science ®Google Scholar
• Quillen K, Lance C, Hu E, Prevalence of ceftriaxone-induced red blood cell antibodies in pediatric patients with sickle cell disease and human immunodeficiency virus infection. Pediatr Infect Dis 2008;28:357-8
   Google Scholar
• Davenport RD, Judd WJ, Dake LR. Persistence of cefotetan on red blood cells. Transfusion 2004;44:849-52
   PubMed Web of Science ®Google Scholar